Baccini Véronique, Geneviève Franck, Jacqmin Hugues, Chatelain Bernard, Girard Sandrine, Wuilleme Soraya, Vedrenne Aurélie, Guiheneuf Eric, Toussaint-Hacquard Marie, Everaere Fanny, Soulard Michel, Lesesve Jean-François, Bardet Valérie
Laboratoire d'hématologie, CHU de la Guadeloupe, INSERM UMR S_1134, 97159 Pointe-à-Pitre, France.
Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), 49033 Angers, France.
J Clin Med. 2020 Mar 16;9(3):808. doi: 10.3390/jcm9030808.
Despite the ongoing development of automated hematology analyzers to optimize complete blood count results, platelet count still suffers from pre-analytical or analytical pitfalls, including EDTA-induced pseudothrombocytopenia. Although most of these interferences are widely known, laboratory practices remain highly heterogeneous. In order to harmonize and standardize cellular hematology practices, the French-speaking Cellular Hematology Group (GFHC) wants to focus on interferences that could affect the platelet count and to detail the verification steps with minimal recommendations, taking into account the different technologies employed nowadays. The conclusions of the GFHC presented here met with a "strong professional agreement" and are explained with their rationale to define the course of actions, in case thrombocytopenia or thrombocytosis is detected. They are proposed as minimum recommendations to be used by each specialist in laboratory medicine who remains free to use more restrictive guidelines based on the patient's condition.
尽管目前不断研发自动化血液分析仪以优化全血细胞计数结果,但血小板计数仍存在分析前或分析过程中的缺陷,包括乙二胺四乙酸(EDTA)诱导的假性血小板减少症。虽然这些干扰大多广为人知,但实验室操作仍高度参差不齐。为了使细胞血液学操作协调一致并实现标准化,说法语的细胞血液学小组(GFHC)希望关注可能影响血小板计数的干扰因素,并详细说明核查步骤,同时给出最少的建议,要考虑到当今所采用的不同技术。此处介绍的GFHC的结论获得了“强烈的专业认可”,并阐述了其原理,以便在检测到血小板减少症或血小板增多症时确定行动方案。这些结论被提议作为最低建议,供每位检验医学专家使用,他们仍可根据患者情况自由采用更严格的指导原则。